CSF rhinorrhoea a rare complication of medical management of giant prolactinomas SFEBES2009 Society for Endocrinology BES 2009

Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. It acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting PRL secretion. In rats the compound decreases PRL secretion at oral doses of 3-25 mcg/kg, and in-vitro at a concentration of 45 pg/ml. In addition, cabergoline exerts a central dopaminergic effect via D2 receptor stimulation at oral doses higher than those effective in lowering serum PRL levels. The long lasting PRL-lowering effect of cabergoline is probably due to its long persistence in the target organ as suggested by the slow elimination of total radioactivity from the pituitary after single oral dose in rats (t½ of approximately 60 hours). Suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg cabergoline given in four divided doses over two days.

  • The pharmacokinetic and metabolic profiles of cabergoline have been studied in healthy volunteers of both sexes and in female hyperprolactinaemic patients.
  • It comes in four different sized bottles with two sizes of plastic syringe to aid the correct dosage.
  • The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week.
  • The effects of alcohol on overall tolerability of cabergoline are currently unknown.

Tolcapone is prescribed by the specialist and requires liver function tests every two weeks during first year of therapy, and thereafter in accordance with the Summary of Product Characteristics. Generally, drug options that may be used as adjuvant therapy to reduce motor complications in later PD include dopamine agonists, MAO-B inhibitors, or COMT inhibitors. Supportive measures should be taken to remove any unabsorbed drug and maintain blood pressure, if necessary.

What is Finilac 50 microgram/ml Oral Solution for Dogs and Cats

The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved. The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week. Doses of cabergoline up to 4.5 mg per week have been used in hyperprolactinaemic patients. Because pregnancy might occur prior to reinitiation of menses, a pregnancy test is recommended at least every four weeks during the amenorrhoeic period and, once menses are reinitiated, every time a menstrual period is delayed by more than three days. Women who wish to avoid pregnancy should be advised to use mechanical contraception during treatment with cabergoline and after discontinuation of cabergoline until recurrence of anovulation.

Improvement in sexual function and testosterone levels within 6 weeks of treatment of hyperprolactinaemia

Since in clinical studies cabergoline has been mainly administered with food and since the tolerability of this class of compounds is improved with food, it is recommended that cabergoline be preferably taken with meals for all the therapeutic indications. https://gasworks.co.uk/uk-englandpharmacy-co-uk-primobolan-steroids/ Drugs not included in the Traffic Light list but included on joint formulary. New drugs classified as red or amber but as greater experience regarding their safety and efficacy is established may move to Green after re-consideration by the HHMC.


Finilac 50 microgram/ml Oral Solution for Dogs and Cats is used to treat false pregnancy in bitches. In bitches and queens – or unspayed cats – it has the effect of suppressing lactation. The solution should be administered orally, directly into the animal’s mouth or by mixing in with their food.